Menin Inhibitors Advance Targeted Treatment Strategies in NPM1-Mutated and KMT2A ...

Menin inhibitors, such as revumenib and ziftomenib, show clinical efficacy in molecularly defined acute myeloid leukemia (AML) with NPM1 mutations and KMT2A rearrangements, while combinations with chemotherapy or azacitidine plus venetoclax are emerging to improve responses and manage resistance.

This Wire brief sits within Fusion42's coverage of Biotech.